生物技术公司Natera, Inc.（纳斯达克股票代码：NTRA）在夜盘交易中股价大涨10.83%，引起投资者广泛关注。这一显著涨幅主要源于公司发布的2025财年第二季度强劲财报，业绩远超市场预期。
根据Natera公布的财报，公司2025财年第二季度实现收入5.47亿美元，同比增长32%，环比增长9%，超出分析师预期。毛利率提升至63.4%，较去年同期的59%有显著改善。公司管理层还上调了全年收入指引至20.2亿至21亿美元，并将毛利率指引提高至61%-64%，展现出对未来业务增长的强烈信心。
Natera的业绩增长主要得益于其肿瘤检测量创下新高，以及改善的报销动态。公司旗舰产品Signatera的测试量达到18.9万次，较去年同期的16.9万次有所增加。管理层表示，未来将继续推出新产品，扩大Medicare覆盖范围，并加大人工智能技术的应用，以进一步提升运营效率和市场竞争力。尽管市场渗透率仍然较低，但Natera管理层对公司在各类肿瘤检测市场的扩张机会持乐观态度，这也增强了投资者对公司长期增长前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.